| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adrenal myelolipomas
|
Calissendorff, Jan
|
|
|
9 |
11 |
p. 767-775
|
artikel
|
| 2 |
COVID-19 and metabolic disease: mechanisms and clinical management
|
Steenblock, Charlotte
|
|
|
9 |
11 |
p. 786-798
|
artikel
|
| 3 |
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
|
Heerspink, Hiddo J L
|
|
|
9 |
11 |
p. 743-754
|
artikel
|
| 4 |
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
|
Jongs, Niels
|
|
|
9 |
11 |
p. 755-766
|
artikel
|
| 5 |
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial
|
Tuttle, Katherine R
|
|
|
9 |
11 |
p. 727-728
|
artikel
|
| 6 |
Impact of the COVID-19 pandemic on transgender and gender diverse health care
|
Burgess, Claire M
|
|
|
9 |
11 |
p. 729-731
|
artikel
|
| 7 |
Insulin analogues: two sides of the same coin
|
The Lancet Diabetes & Endocrinology,
|
|
|
9 |
11 |
p. 725
|
artikel
|
| 8 |
Obesity in people living with type 1 diabetes
|
Van der Schueren, Bart
|
|
|
9 |
11 |
p. 776-785
|
artikel
|
| 9 |
Sherita Hill Golden: tackling the source of health disparities
|
Cavanaugh, Ray
|
|
|
9 |
11 |
p. 732
|
artikel
|
| 10 |
Statins for Graves' orbitopathy: a new tool for prevention and treatment?
|
Bartalena, Luigi
|
|
|
9 |
11 |
p. 726-727
|
artikel
|
| 11 |
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial
|
Lanzolla, Giulia
|
|
|
9 |
11 |
p. 733-742
|
artikel
|
| 12 |
The digital frontier: bringing one generation to the next
|
The Lancet Diabetes & Endocrinology,
|
|
|
9 |
11 |
p. 725
|
artikel
|
Tijdschrift beschrijving